Skip to Content

How much does Blincyto (blinatumomab) cost?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on March 9, 2021.

Official Answer

by Drugs.com

The cost of a Blincyto (blinatumomab) vial is $4,438.25 per 35 microgram (mcg) single-dose vial.

  • This cash price can vary based upon your insurance, your clinic cost, and any administration fees for the injection and clinic or hospital use.
  • The overall cost for your therapy will also depend upon the length of treatment.
  • Most people do not pay out-of-pocket for the full price of Blincyto.

When Blincyto was first approved by the FDA, Amgen announced that the price for the drug at that time would be $178,000 per year.

This drug is usually given by a health care provider in a clinic or hospital and is not found in a traditional pharmacy. The cost for this medicine may be covered by your insurance but you may have a deductible, copay or coinsurance.

This Blincyto price is based on using the Drugs.com discount card.

Can I get help paying for Blincyto?

Blincyto is manufactured by Amgen, who may be able to provide financial assistance to help cover some or all of the cost of Blincyto. Contact them to learn more about the Amgen Assist 360 program or other options to determine if you are eligible.

If you have commercial insurance, you may qualify for the Amgen First-Step Program which may be able to provide funds to help you pay your deductible, copay, or coinsurance. For example, with the Amgen First-Step Program, there is:

  • $0 out-of-pocket for first dose or cycle
  • $5 out-of-pocket for subsequent doses or cycles, up to the brand program maximum
  • no income eligibility requirement

If you have government insurance like Medicare, Amgen may be able to refer you to nonprofit patient assistance programs to help you afford your copays.

If you have no insurance, contact Amgen to determine if you qualify for Amgen medicines at no cost to you.

To learn more: call 1-888-4ASSIST (1-888-427-7478), Monday to Friday 9:00 am to 8:00 pm ET.

What is Blincyto used for?

Blincyto is a prescription medicine used to treat adults and children with:

  • B-cell precursor acute lymphoblastic leukemia (ALL) in remission with molecular evidence of leukemia
  • B-cell precursor ALL that has come back or did not respond to previous treatments

Acute lymphoblastic leukemia is a cancer of the blood that starts when a certain kind of white blood cell starts growing out of control.

Blincyto is classified as a bispecific CD19-directed CD3 T-cell engager (or BiTE antibody). Blincyto is considered an immunotherapy anticancer treatment but it is not a traditional chemotherapy medicine. Immunotherapy uses the body’s own immune system to better target cancer cells.

How is Blincyto given?

Blincyto is given by a continuous intravenous (IV) infusion into your vein by a special pump. Your healthcare provider will determine how much medicine to give you and how often you will receive treatment.

You may receive Blincyto in a hospital or clinic so your healthcare provider can check you for side effects.

Learn more: FDA Approved Blincyto Patient Medication Guide

This is not all the information you need to know about Blincyto (blinatumomab) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Blincyto information here, and discuss this information and any questions you have with your doctor or other health care provider.

References

Related Medical Questions

Drug Information

Related Support Groups